EWTX•benzinga•
Edgewise Therapeutics Sees Meaningful HCM Treatment Gains With EDG-7500 In Phase 2 Study
Summary
Edgewise's EDG-7500 lowered LVOT gradient and NT-proBNP levels in HCM patients, improving symptoms. Initial Part D data is expected in late 2025.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on April 2, 2025 by benzinga